Results From 10-Patient Case Study Lead to Phase III Clinical Trial for Patients with Duchenne Muscular Dystrophy
Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with
Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.
Muscle weakness begins in early childhood, often causing deformity of the arms, legs and spine. Heart and respiratory muscles often begin to fail before children reach early teen years. Although steroid medications – which often are not well tolerated – and other therapies may ease symptoms and delay the most severe effects, no disease-specific treatment exists, and patients rarely survive into their 30s.
But in this case study of 10 boys with Duchenne muscular dystrophy, also called DMD, a single dose of a drug often prescribed for erectile dysfunction or pulmonary hypertension corrected defective blood vessel mechanisms and restored blood flow to exercising muscles.
“The effects were immediate and dramatic, raising the question: If a single dose restores blood flow to muscle while the drug is in the patient’s system, could ongoing tadalafil administration provide sustained benefits, possibly preserve muscle and slow disease progression? If so, this would offer a new therapeutic strategy for DMD, and we have launched a randomized Phase III clinical trial to find out,” said Ronald Victor, MD, director of the Cedars-Sinai Center for Hypertension, associate director of clinical research at the Heart Institute and the Burns and Allen Chair in Cardiology Research. He is the senior author of a highlighted article in the May 7 online edition of Neurology.
Duchenne muscular dystrophy results from a genetic defect that eliminates a protein called dystrophin in the membranes of muscle cells. For more than 25 years, Victor has studied DMD and a less aggressive but debilitating variant called Becker muscular dystrophy. This form of muscular dystrophy, usually diagnosed in early adulthood, is caused by a reduction, but not absence, of dystrophin.
Victor led a research team that in 2000 discovered that the blood flow abnormality in the muscles of children with DMD was caused by a loss of nitric oxide, a signaling chemical that normally tells blood vessels to relax during exercise, increasing blood flow and oxygenation.
In studies of mice bred to represent diseases of dystrophin deficiency, the researchers found that drugs prescribed for other disorders of blood vessel function could restore muscle blood flow and enable the animals to exercise more, with less muscle injury. Tadalafil, known by the brand names Cialis and Adcirca, and sildenafil, called Viagra and Revatio, have long been approved by the Food and Drug Administration to treat erectile dysfunction and pulmonary hypertension, a serious illness that restricts blood flow to the lungs.
Translating these findings to a human clinical trial, Victor and his colleagues published in 2012 a study showing that tadalafil fully restored blood flow in eight of nine patients with Becker muscular dystrophy.
In the new study, investigators found that when boys with Duchenne muscular dystrophy performed handgrip exercises, the major artery of the arm and the blood vessels in muscles of the forearm failed to respond the way they did in healthy boys of similar ages, 8 to 13. But when the boys with DMD were given a single dose of tadalafil, normal vessel function and blood flow were restored. Similar results occurred when sildenafil, a drug with a similar mechanism of action on vessels but a different chemical structure, was used in place of tadalafil.
“Steroids and cardiac-protective blood pressure medication are increasingly prescribed at early ages for patients with Duchenne muscular dystrophy in an effort to delay by a few years the most devastating effects of the disease. But these treatments have no effect on the blood vessel dysfunction that prevents muscles from getting the oxygen they need,” said Victor. “In contrast, in our study, a single dose of tadalafil or sildenafil had an immediate effect. These are well-studied, well-tolerated drugs that are already on the market. If additional study confirms their benefits, repurposing the drugs for muscular dystrophy patients could quickly transform clinical practice.”
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Gene therapeutic strategies and relevant clinical trials in neuromuscular disorder in Chinaon June 26, 2020 at 8:20 am
Neuromuscular disorder is a diverse group of genetic disease, among which Duchenne muscular dystrophy and Spinal muscular atrophy are most common. Recently, the great breakthroughs of gene targeted ...
- 2025: Duchenne Muscular Dystrophy Therapeutics Market share will be valued for USD 2629.3 Million with top players analysison June 23, 2020 at 10:40 pm
The research report on Duchenne Muscular Dystrophy Therapeutics Market is an analysis and information corresponding to market segments such as geographies, product type, application, and end-use ...
- Duchenne Muscular Dystrophy Treatment Market | Global Industry Analysis By Size, Growth Rate and Trends With Forecast 2020 To 2026on June 23, 2020 at 12:46 am
Duchenne Muscular Dystrophy Treatment Market- 2020 Global Industry Trends, Size, Share Analysis Report. According to ...
- UK’s MHRA renews EAMS Scientific Opinion for Santhera’s Idebenone in Duchenne Muscular Dystrophyon June 22, 2020 at 10:13 pm
Stock quotes by finanzen.net Pratteln, Switzerland, June 23, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has renewed ...
- Neuromuscular specialist tapped for Edgewise top medical positionon June 22, 2020 at 10:00 am
Edgewise Therapeutics Inc., a Boulder pharmaceutical firm developing small molecule therapies for musculoskeletal diseases, has hired Dr. Kirsten Gruis as chief medical officer. Gruis, a physician ...
- Sarepta tries to fine-tune its gene therapy approachon June 22, 2020 at 9:59 am
Research deals with Codiak Biosciences and Selecta Biosciences could help Sarepta work around a key challenge in gene therapy development.
- Team Joseph Unites With Duchenne Muscular Dystrophy Community to Help Families During COVID-19on June 16, 2020 at 8:39 am
Having a child with a severe medical condition like Duchenne muscular dystrophy brings a whole new set of challenges, especially durin ...
- Newry boy Alfie Pentony (7) runs marathon distance to fund breakthrough US treatment for his Duchenne muscular dystrophyon June 15, 2020 at 11:08 pm
A primary school pupil from Co Down is running the length of a marathon to raise funds for his battle against a muscle wasting disease.
- Micro-dystrophin gene therapy can improve outcomes in children with Duchenne muscular dystrophyon June 15, 2020 at 11:04 pm
Researchers from Nationwide Children's Hospital have published in JAMA Neurology results from the first four patients treated in the first clinical trial of systemic delivery of micro-dystrophin gene ...
- Sarepta's Gene Therapy for Duchenne Muscular Dystrophy Clears a Major Safety Hurdleon June 15, 2020 at 1:02 pm
A once-and-done gene therapy candidate that could halt the progression of a lethal muscle-wasting disorder took an important step on the path toward approval Monday. Results of a clinical trial ...
via Bing News